Loading...

ALZN ALZAMEND NEURO INC US FDA Inspections 8-K Filing

LZMN

LZN

ALZAMEND NEURO INC

(ALZN)

2023 8-K

Show Summary

Show Summary

Bylaws Amendment

Share Exchange Agreement

Financial Results

Nasdaq Compliance

Compliance Regained and Soc...

Amendment to Certificate of...

Special Meeting of Stockhol...

Presentation Update

Annual Meeting Adjournment

Agreement for Sale of Prefe...

Dismissal and Appointment o...

Termination of Agreement

Material Definitive Agreement

Equity Sale and Delisting N...

Warrant Amendment Agreement...

Amended Certificate of Desi...

Agreement with Ault Lending...

Appointment of Director and...

Reverse Stock Split

Delisting Notice

Social Media Communication

Delisting - Non-Compliance

Positive Clinical Trial Res...

Annual Meeting Results

Regulation FD Disclosure

Clinical Trial Initiation

Clinical Trial Completion

Earnings Report

Delisting Notice

Regulation FD Disclosure

External Links:

Alzamend Neuro, Inc. completed the clinical portion of its Phase IIA multiple ascending dose clinical trial for AL001 treatment of dementia related to Alzheimer's disease and expects to report topline data in June 2023.

AI Assistant

ALZAMEND NEURO INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.